Masahiko Watanabe

Masahiko Watanabe

Auto-generated profile, based on publicly available information

Masahiko Watanabe

Department of Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2021 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
HSHidefumi Shiroshita
Hidefumi Shiroshita
MIMasafumi Inomata
Masafumi Inomata
SAShigeo Akira
Shigeo Akira
HKHiroomi Kanayama
Hiroomi Kanayama
SYShigeki Yamaguchi
Shigeki Yamaguchi
YSYoshiharu Sakai
Yoshiharu Sakai

5 March 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MWMina Waraya
Mina Waraya
KYKeishi Yamashita
Keishi Yamashita
HKHiroyuki Katagiri
Hiroyuki Katagiri
KIKenichiro Ishii
Kenichiro Ishii
YTYoshihito Takahashi
Yoshihito Takahashi
MWMasahiko Watanabe
Masahiko Watanabe

15 March 2010 in Oncogene
Verified
Journal Article
Open access
PDF file
AOA Ooki
A Ooki
KYK Yamashita
K Yamashita
SKS Kikuchi
S Kikuchi
SSS Sakuramoto
S Sakuramoto
NKN Katada
N Katada
MWM Watanabe
M Watanabe
HOP homeobox (HOPX) is an unusual homeobox gene encoding three spliced transcript variants, among which the only HOPX-β promoter harbors CpG islands. The characteristics of its promoter methylation was analyzed using bisulfite sequencing and quantitative-methylation-specific polymerase chain reaction (Q-MSP), and the effects of HOPX expression were also examined. HOPX-β expression was silenced in all gastric cancer cell lines tested; its expression could be restored by treatment with demethylating agent. On Q-MSP, HOPX-β hypermethylation (cut-off value of 3.55) was found in 84% (67 out of 80) of primary tumor tissues and 10% (8 out of 80) of the corresponding normal tissues and could discriminate normal from tumor tissues (P<0.0001). The prognosis of the advanced cases with HOPX-β hypermethylation was as poor as those with stage IV disease when cut-off value was set at 11.28. This finding was validated in an independent cohort of 90 advanced gastric cancers. The HOPX-β hypermethylation was also an independent prognostic factor (P=0.029) on multivariate analysis. Exogenous HOPX expression significantly inhibited cell proliferation, colony formation and invasion as well as enhanced apoptosis. Taken together, HOPX-β promoter methylation is a frequent and cancer-specific event in gastric cancer. Quantitative assessment of HOPX-β methylation has great clinical potential as a marker of tumor aggressiveness.

18 November 2010 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
HKHiroshi Katoh
Hiroshi Katoh
KYKeishi Yamashita
Keishi Yamashita
GWGuoqin Wang
Guoqin Wang
TSTakeo Sato
Takeo Sato
TNTakatoshi Nakamura
Takatoshi Nakamura
MWMasahiko Watanabe
Masahiko Watanabe

1 July 2012 in Neoplasia
Verified
Journal Article
Open access
PDF file
HKHiroshi Katoh
Hiroshi Katoh
KYKeishi Yamashita
Keishi Yamashita
MWMina Waraya
Mina Waraya
OMOfer Margalit
Ofer Margalit
AOAkira Ooki
Akira Ooki
MWMasahiko Watanabe
Masahiko Watanabe
Neoplasia publishes the results of novel investigations in all areas of oncology research.

1 June 2018 in European Journal of Cancer
Verified
Journal Article
Open access
CMChu Matsuda
Chu Matsuda
MIMegumi Ishiguro
Megumi Ishiguro
STSatoshi Teramukai
Satoshi Teramukai
YKYoshiki Kajiwara
Yoshiki Kajiwara
SFShoichi Fujii
Shoichi Fujii
KSKenichi Sugihara
Kenichi Sugihara
Efficacy of adjuvant chemotherapy in patients with stage II colon cancer is still controversial. The SACURA trial is a randomised-controlled study evaluating the superiority of 1-year adjuvant treatment with oral tegafur-uracil (UFT) to surgery alone for stage II colon cancer. Patients were randomly assigned to the surgery-alone group or UFT group (UFT at 500-600 mg/day for 5 days, followed by 2-day rest, for 1 year). The primary end-point was disease-free survival (DFS). Target sample size was 2000, determined with one-sided alpha of 0.05, power of 0.9 and assumed hazard ratio (HR) 0.729. A total of 1982 patients (997 in the surgery-alone group and 985 in the UFT group) were analysed. Median follow-up was 69.5 months, median age was 66 years and for stage IIA/IIB/IIC, the distribution was 84%/13%/3%. The 5-year DFS rate was 78.4% in the surgery-alone group and 80.2% in the UFT group. The HR for DFS was 0.91 (95% confidence interval [CI], 0.75-1.10; p = 0.31); superiority of UFT was not demonstrated. Approximately 9% of patients experienced second cancers, which consist 40.7% of the DFS events. The 5-year relapse-free and overall survival rates of the surgery-alone and UFT group were 84.6% and 87.2% (HR, 0.82; 95% CI, 0.65-1.04) and 94.3% and 94.5% (HR, 0.93; 95% CI, 0.66-1.31), respectively. Subgroup analysis failed to disclose superiority in prognosis of adding UFT to the patients with risk factors for recurrence. Superiority of 1-year adjuvant UFT over surgery alone was not demonstrated in stage II colon cancer. Patients with risk factors for recurrence did not benefit from UFT. ClinicalTrials. Gov. #NCT00392899.